Saturday 26.10.2024

Scientific Session Satellite Symposium Main Program Educational Workshop
calendar export icon Export calendar
Session details 08:30–11:00
Workshop 1 (Parallel Sessions)

Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma

Room:Marsilius Saal (Gürzenich) Separate registration required Separate registration required
Session details 08:30–11:00
Educational (Parallel Sessions)

EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas”

Room:Großer Saal (Gürzenich)
  • 08:30

    Introduction

  • 08:33

    Molecular and microenvironmental vulnerabilities of B-cell lymphomas

  • 08:55

    Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma?

  • 09:17

    Who needs bispecific antibodies as first-line treatment in aggressive lymphoma?

  • 09:39

    How to implement novel ADCs in the first-line treatment of lymphoma

  • 10:01

    Perspectives of small molecule based first-line therapy of LBCL

  • 10:23

    Treatment and Trial Landscape for Malignant Lymphoma in China

Session details 11:30–13:00
Scientific Session 1

Limited Stages

Room:Großer Saal (Gürzenich)
Session details 13:15–14:45
Satellite Symposium

The evolving role of BTKis in the treatment of B-cell lymphomas

Room:Großer Saal (Gürzenich)
Session details 15:15–17:00
Main Program

Opening and Award Ceremony

Room:Großer Saal (Gürzenich)
Session details 17:15–20:00
Main Program

Poster Session & Welcome Reception

Room:Foyer (First Floor) (Gürzenich)
  • All poster presenters are required to be present at their poster boards from 17:15 to 19:00

Sunday 27.10.2024

Scientific Session Satellite Symposium Main Program Educational Workshop
calendar export icon Export calendar
Session details 08:00–09:30
Scientific Session 2

Pediatric and Adolescent Treatment Concepts

Room:Großer Saal (Gürzenich)
  • 08:00

    Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective

  • 08:20

    Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective

  • 08:40

    Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization

  • 09:30

    abstract talk Abstract Talk: T086 EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY

  • 09:40

    abstract talk Abstract Talk: T087 Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

  • 09:50

    abstract talk Abstract Talk: T088 Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

Session details 10:00–11:30
Scientific Session 3

Biology & Microenvironment

Room:Großer Saal (Gürzenich)
Session details 12:00–13:30
Satellite Symposium

New concepts for the treatment of B-cell lymphomas

Room:Großer Saal (Gürzenich)
  • 12:00

    B-cell lymphoma pathology – illustrated for non- pathologists

  • 12:30

    Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade

  • 13:00

    Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapies

Session details 14:00–15:30
Scientific Session 4

Older Patients

Room:Großer Saal (Gürzenich)
Session details 16:00–17:30
Satellite Symposium

Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma

Room:Großer Saal (Gürzenich)
  • 16:00

    Welcome and introduction

  • 16:05

    Spotlight on ECHELON-1: 7-year survival data

  • 16:15

    Real-world insights: frontline treatment of stages III & IV cHL

  • 16:45

    Q&A

  • 17:00

    cHL in the real-world: a case study approach

Session details 18:00–19:30
Scientific Session 5

Advanced Stages

Room:Großer Saal (Gürzenich)

Monday 28.10.2024

Scientific Session Satellite Symposium Main Program Educational Workshop
calendar export icon Export calendar
Session details 08:00–09:00
Scientific Session 6

Special Situations & Cases

Room:Großer Saal (Gürzenich)
Session details 09:15–10:15
Scientific Session 7

NLPHL

Room:Großer Saal (Gürzenich)
Session details 10:30–12:00
Scientific Session 8

Living Beyond Lymphoma

Room:Großer Saal (Gürzenich)
  • 10:30

    Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)

  • 10:50

    Starting Living beyond Lymphoma with HL diagnosis

  • 11:10

    Participation in and (cost-)effectiveness of the Dutch HL survivorship care program

  • 12:00

    abstract talk Abstract Talk: T062 A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations

  • 12:10

    abstract talk Abstract Talk: T063 Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

  • 12:20

    abstract talk Abstract Talk: T064 Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors

Session details 12:30–14:00
Scientific Session 9

Relapsed & Refractory HL

Room:Großer Saal (Gürzenich)
  • 12:30

    Updated approach to second-line treatment

  • 12:50

    Emerging strategies to overcome anti-PD1 resistance

  • 13:10

    Implementing raditoherapeutic concepts in rrHL care

  • 14:00

    abstract talk Abstract Talk: T104 Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.

  • 14:10

    abstract talk Abstract Talk: T105 Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients

  • 14:20

    abstract talk Abstract Talk: T106 Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

Session details 14:00
Main Program

Closing remarks

Room:Großer Saal (Gürzenich)

Gürzenich: Basement

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Gürzenich: Basement Wardrobe Go to Ground Floor Go to Ground Floor Gürzenich: Basement

Gürzenich: Ground Floor

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Gürzenich: Ground Floor PC Pool / Internet Registration Speakers Ready Room Go to First Floor Go to Basement Go to First Floor Go to Basement Marsilius Saal Gürzenich: Ground Floor

Gürzenich: First Floor

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Gürzenich: First Floor Go to Ground Floor Go to Ground Floor Großer Saal Isabellensaal Foyer (First Floor) Gürzenich: First Floor

Exhibition

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Map of the exhibition. Map of the Gürzenich: First Floor showing the location of 7 exhibitors. Stair to Ground Floor Stair to Ground Floor Großer Saal Isabellensaal Foyer (First Floor)

Limited stages

Selected for Oral Presentation

  • Show Details

    T049 (T049) Factors driving treatment intensity in the whole cohort of patients with early-stage favorable (I-IIA), nonbulky Hodgkin Lymphoma enrolled in the RAFTING trial (NCT 04866654).

    • Jan Maciej Zaucha
    • Marco Picardi
    • Kateryna Filonenko
    • Manuel Gotti
    • Javier Nunez
    • Andrea Rossi
    • Eva Domingo-Domènech
    • Agnieszka Giza
    • Roberto Sorasio
    • Andrea Visentin
    • Mariana Bastos
    • Ewa Paszkiewicz-Kozik
    • Ramon Garcia-Sanz
    • Caterina Patti
    • Stephane Chauvie
    • Fabrizio Bergesio
    • Luca Guerra
    • Anna Sureda
    • Andrea Gallamini
  • Show Details

    T050 (T050) Nodular lymphocyte predominant Hodgkin lymphoma in the Nordic countries – characteristics, treatment and survival

    • Kossi D Abalo
    • Katrin Bamdeg-Hvolbek
    • Frida Ekeblad
    • Ilja Kalashnikov
    • Johan Linderoth
    • Dennis Lund Hansen
    • Gunilla Enblad
    • Urban Jerlstrom
    • Christina Goldkuhl
    • Taina Reunamo
    • Marjukka Pollari
    • Martin Hutchings
    • Peter Kamper
    • Rasmus Bo Dahl-Sørensen
    • Ingemar Lagerlöf
    • Ann-Sofie Johansson
    • Lotta Hansson
    • Daniel Molin
    • Sirpa M. Leppä
    • Tarec Christoffer El-Galaly
    • Ingrid Glimelius
  • Show Details

    T051 (T051) Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume During Anti-PD1-Based First-Line HL Treatment in The GHSG Phase II NIVAHL Trial

    • Wouter J. Plattel
    • Sophie Teesink
    • Lydia Visser
    • Conrad-Amadeus Voltin
    • Helen Kaul
    • Hans A. Schlösser
    • Bart-Jan Kroesen
    • Carsten Kobe
    • Peter Borchmann
    • Arja Diepstra
    • Paul J. Bröckelmann

Posters

  • Show Details

    P052 (P052) AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

    • Jennifer Seelisch
    • Boyu Hu
    • Lindsay A. Renfro
    • Frank G. Keller
    • Adam DuVall
    • Tara O. Henderson
    • Yue Wu
    • Steve Yoon-Ho Cho
    • Bradford S. Hoppe
    • Sarah Milgrom
    • Lisa Giulino Roth
    • Natalie S. Grover
    • Ann S. LaCasce
    • Justine M. Kahn
    • Song Yao
    • Susan K. Parsons
    • Niloufer Khan
    • Raymond Mailhot Vega
    • Pamela S. Hinds
    • Pamela B. Allen
    • Andrew M. Evens
    • Heiko Schoder
    • Sharon M. Castellino
    • Kara M. Kelly
  • Show Details

    P053 (P053) Development and validation of the Early stage (ES) classic Hodgkin Lymphoma (cHL) International Prognostication Index (E-HIPI): an individualized prediction model for progression-free survival (PFS) utilizing objective and continous variables

    • Angie Mae Rodday
    • John Radford
    • Matthew Maurer
    • Jenica Upshaw
    • Nicholas Counsell
    • Sara Rossetti
    • Ranjana H. Advani
    • Marc Andre
    • Cheryl Chang
    • Andrea Gallamini
    • Annette Hay
    • David Hodgson
    • Richard Hoppe
    • Martin Hutchings
    • Peter Johnson
    • Eric Mou
    • Stephen Opat
    • John M.M. Raemaekers
    • Kerry Savage
    • Qingyan Xiang
    • Susan K. Parsons
    • Andrew Evens
  • Show Details

    P054 (P054) Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial (Trial in Progress)

    • Paul J. Bröckelmann
    • Helen Kaul
    • Michael Fuchs
    • Carsten Kobe
    • Christian Baues
    • Wolfram Klapper
    • Bastian von Tresckow
    • Peter Borchmann
  • Show Details

    P055 (P055) King Faisal Specialist Hospital and Research Centre

    • Reyad Dada
    • John Apostolidis
    • Refaei Belal Ibrahim
    • Asma Ahmed Salem
    • Mostafa Ibrahim Mahmoud
    • Hafiz Asif Iqbal
    • Tarik Boubakra
    • Hamza Ghatasheh
    • Azahr Nawaz
    • Khalid Halahleh
  • Show Details

    P056 (P056) Pediatric Infradiaphragmatic Hodgkin’s lymphoma: a unique identity

    • Asmaa Hamoda
    • Nashwa Ezzeldeen
    • Emad Moussa
    • Madeeha A.T. El Wakeel
    • Eman Khorshed
    • Maha Mehesen
    • amr elnashar
    • Sara abdelkareem
    • Mohamed Zaghloul
  • Show Details

    P057 (P057) Proton therapy for limited stage classical Hodgkin lymphoma patients (PRO-Hodgkin): an interim analysis of clinical outcome.

    • Christina Goldkuhl
    • Anna Bäck
    • Gunilla Enblad
    • Ingrid Glimelius
    • Lotta Hansson
    • Urban Jerlström
    • Ann-Sofie Johansson
    • Jenny Kahlmeter-Brandell
    • Johan Linderoth
    • Marzia Palma
    • Daniel Molin
  • Show Details

    P058 (P058) Real-life data on morbidity and cause-specific mortality after combined modality treatment for classical Hodgkin lymphoma 2006-2015.

    • Ingemar Lagerlöf
    • Per Wikman
    • Gunilla Enblad
    • Christina Goldkuhl
    • Marzia Palma
    • Helena Fohlin
    • Ingrid Glimelius
    • Daniel Molin
  • Show Details

    P059 (P059) Safe Radiotherapy for Pregnant Women with Hodgkin's Lymphoma: Myth or Reality?

    • Elżbieta Wojciechowska-Lampka
    • Magdalena Rosińska
    • Jacek Lampka
    • Włodzimierz Osiadacz
    • Joanna Tajer
    • Agnieszka Kuchcińska
  • Show Details

    P060 (P060) Total metabolic tumor volume impairs the successful detection of circulating tumor DNA (ctDNA) in early-stage Hodgin lymphoma patients – the preliminary report from the RAFTING trial.

    • Marta Bednarek
    • Stephane Chauvie
    • Maria Pirosa
    • Luca Guerra
    • Annibale Versari
    • Michele Gregianin
    • Fabrizio Bergesio
    • Katia Pini
    • Georgia Alice Galimberti
    • Simone Bocchetta
    • Matin Salehi
    • Adam Wyszomirski
    • Alessandro Rambaldi
    • Marco Picardi
    • Kateryna Filonenko
    • Michał Kurlapski
    • Anna Sureda
    • Davide Rossi
    • Andrea Gallamini
    • Jan Maciej Zaucha
  • Show Details

    P061 (P061) Variation in the delivery of radiotherapy as part of frontline curative treatment for Hodgkin lymphoma across healthcare providers in England

    • David Jones
    • Philip Clarke
    • Jane Wolstenholme
    • David Cutter
    • John Broggio

Pediatric and adolescent

Selected for Oral Presentation

  • Show Details

    T086 (T086) EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY

    • Dieter Körholz
    • Maurizio Mascarin
    • Judith Landman-Parker
    • Thierry Leblanc
    • Lars Kurch
    • Thomas W. Georgi
    • Regine Kluge
    • Dietrich Stoevesandt
    • Tanja Pelz
    • Dirk Vordermark
    • Karin Dieckmann
    • Stephen Daw
    • Ana Fernandez-Teijeiro
    • Galia Avrahami
    • Leanne Super
    • Auke Beishuizen
    • Walentyna Balwierz
    • Tomasz Klekawka
    • Anne Uyttebroeck
    • Andishe Attarbaschi
    • Michaela Cepelova
    • Francesco Ceppi
    • Alexander Fosså
    • Tim Prestidge
    • Annika Englund
    • Lisa Lyngsie Hjalgrim
    • Wolfram Klapper
    • Dirk Hasenclever
    • Christine Mauz-Körholz
  • Show Details

    T087 (T087) Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

    • Sharon M. Castellino
    • Hongli Li
    • Alex F. Herrera
    • Angela Punnett
    • Michael Le
    • Susan K. Parsons
    • Frank G. Keller
    • Richard Drachtman
    • Adam Lamble
    • Christopher J. Forlenza
    • Andrew Doan
    • Sarah Rutherford
    • Andrew Evens
    • David Hodgson
    • Richard F. Little
    • Malcom Smith
    • Hildy Dillon
    • Joo Song
    • Sonali Smith
    • Jonathan W. Friedberg
    • Kara M. Kelly
  • Show Details

    T088 (T088) Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

    • Lisa Giulino-Roth
    • Mario Melgar Toledo
    • Frank G. Keller
    • Bradford S. Hoppe
    • Christopher J. Forlenza
    • Sharon M. Castellino
    • Maitane Andion Catalan
    • Julie Krystal
    • Adam Lamble
    • Flavio Luisi
    • Fabio Molina Morales
    • Aarati V. Rao
    • Stacy Cooper
    • Oscar Gonzalez-Llano
    • Luis Juarez Villegas
    • Christine Mauz-Körholz
    • Juan Shen
    • Pallavi Pillai
    • Rushdia Yusuf
    • Kara M. Kelly

Posters

  • Show Details

    P089 (P089) An audit of compliance with recommendations for screening and management of Hodkins lymphoma in teenager and young adult population. Results from a baseline audit within the northern health and social care trust.

    • Esraa Yousif
    • Kerrie Sweeney
    • Aaron Niblock
  • Show Details

    P090 (P090) Brentuximab-Associated Alopecia in Children and Young Adults with Newly Diagnosed Hodgkin Lymphoma

    • Jonathan D. Bender
    • Angela T. Faulhaber
    • Robin E. Norris
  • Show Details

    P091 (P091) Clinical study of immune-targeting combined with attenuated chemotherapy in the treatment of pediatric Hodgkin lymphoma

    • Huixia Gao
    • Yanlong Duan
  • Show Details

    P092 (P092) Award winning CNS Involvement in Pediatric Hodgkin Lymphoma: A Retrospective Analysis of AHOD1331, EuroNet-PHL-C1 and EuroNet-PHL-C2 from SEARCH for CAYAHL

    • Reena Pabari
    • Kathleen McCarten
    • Jamie E. Flerlage
    • Hollie Lai
    • Christine Mauz-Körholz
    • Karin Dieckmann
    • Monica Palese
    • Sue C. Kaste
    • Sharon M. Castellino
    • Kara M. Kelly
    • Dietrich Stoevesandt
    • Lars Kurch
  • Show Details

    P093 (P093) Definition of independent lymph node regions in pediatric HL. An expert consensus by an International Collaboration on Staging Evaluation and Response Criteria Harmonization (SEARCH) for Children, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL)

    • Dietrich Stoevesandt
    • Jonas Steglich
    • Lars Kurch
    • Jamie E. Flerlage
    • Christine Mauz-Körholz
    • Dieter Körholz
    • Regine Kluge
    • Dirk Vordermark
    • Bradford S. Hoppe
    • Karin Dieckmann
    • Claire Gowdy
    • Stephan Voss
  • Show Details

    P094 (P094) Dose-dense chemotherapy enables elimination of radiotherapy for a majority of patients with low-risk pediatric Hodgkin lymphoma: a report on HOD08 from the Pediatric Hodgkin Consortium

    • Jamie E. Flerlage
    • Angela Feraco
    • Yiwang Zhou
    • Ying Zheng
    • Lia Jiang
    • John Lucas
    • Alison Friedmann
    • Howard Weinstein
    • Torunn Yock
    • Barry Shulkin
    • Sue C. Kaste
    • Lianna Marks
    • Matthew Ehrhart
    • Stephanie Dixon
    • Scott Howard
    • Pedro de Alarcon
    • Sandra Luna-Fineman
    • Amy Geddis
    • Eric Larsen
    • Karen Marcus
    • Amy Billett
    • Sarah Donaldson
    • Melissa Hudson
    • Monika Metzger
    • Matthew Krasin
    • Michael Link
  • Show Details

    P095 (P095) Group-Based Trajectories of Health-related Quality of Life (HRQoL) among Patients with High-Risk Pediatric Hodgkin Lymphoma treated on the Children’s Oncology Group (COG) AHOD 1331 Study

    • AnnaLynn Williams
    • Angie Mae Rodday
    • Lindsay A. Renfro
    • Yue Wu
    • Tara O. Henderson
    • Frank G. Keller
    • Kara Kelly
    • Sharon M. Castellino
    • Susan K. Parsons
  • Show Details

    P096 (P096) International Harmonization Efforts for Pediatric, Adolescent and Young Adult Hodgkin Lymphoma: A Current Report from the SEARCH FOR CAYAHL Group

    • Jennifer Seelisch
    • Kara M. Kelly
    • Angela Punnett
    • Christine Mauz-Körholz
    • Lianna Marks
    • Monica Palese
    • Reena Pabari
    • Karin Dieckmann
    • Hollie Lai
    • Claire Gowdy
    • Jonas Steglich
    • Richard Drachtman
    • Stephan D Voss
    • Bradford S. Hoppe
    • Kathleen McCarten
    • Lars Kurch
    • Auke Beishuizen
    • Dietrich Stoevesandt
    • Jamie E. Flerlage
  • Show Details

    P097 (P097) Is the EVA regimen (etoposide, vinblastine, doxorubicin) safe and effective for treating Hodgkin's lymphoma in pregnant patients?

    • Elżbieta Wojciechowska-Lampka
    • Magdalena Rosińska
    • Jacek Lampka
    • Zbigniew Nowecki
    • Włodzimierz Osiadacz
    • Joanna Tajer
    • Joanna Romejko-Jarosińska
  • Show Details

    P098 (P098) Omitting radiation in young adult females with Hodgkin’s disease, Is there an impact on outcome?

    • Asmaa Hamoda
    • samah semary
    • eman naguib
    • Madeeha A.T. El Wakeel
    • mohamed zaghloul
    • salma abdelaziz
    • mahmoud hamza
    • Emad Moussa
  • Show Details

    P099 (P099) PET/CT Response Assessment in Pediatric Hodgkin Lymphoma. Deauville Score 3 Does it really reflect Negativity?

    • Emad Moussa
    • Asmaa Hamoda
    • samah semary
    • maram salama
    • mona fakhry
    • maha mehesen
    • madeeha elwakeelc
    • eman naguib
    • amr elnashar
    • asmaa Attia
    • mohamed sedky
  • Show Details

    P100 (P100) Prognostic Significance of PD1, PD-L1 Expression, Pathological Subtypes and Metabolic Activity on 18F-FDG PET/CT in Refractory/Relapsing Pediatric Hodgkin Lymphoma

    • Reham Khedr
    • Eman Khorshed
    • Omneya Hassanein
    • Hany Abdelrahman
    • Madeeha A.T. El Wakeel
    • Mohamed Zaghloul
    • Asmaa Hamoda
  • Show Details

    P101 (P101) Towards Incorporation of Pediatric Specific Criteria in the Revised Lugano Classification of Hodgkin Lymphoma (HL) Staging and Response: Report from the ICML Pediatric Subcommittee

    • Kara M. Kelly
    • Jamie E. Flerlage
    • Bradford S. Hoppe
    • Regine Kluge
    • Christine Mauz-Körholz
    • Wilhelm Wößmann
  • Show Details

    P102 (P102) Award winning Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Sub-Study of Children’s Oncology Group AHOD0431

    • Bradford S. Hoppe
    • Sarah Milgrom
    • Lindsay A. Renfro
    • Yue Wu
    • Cindy Schwartz
    • Louis Constine
    • David Hodgson
    • Kathleen McCarten
    • Kara M. Kelly
    • Frank G. Keller
    • Sharon M. Castellino
  • Show Details

    P103 (P103) Updated Results From the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With High-Risk Classical Hodgkin Lymphoma (cHL) With Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

    • Christine Mauz-Körholz
    • Luciana Vinti
    • Stephen Daw
    • Antony Ceraulo
    • Gerard Michel
    • Michaela Cepelova
    • Constantino Sabado Alvarez
    • Franca Fagioli
    • Stephane Ducassou
    • Salvatore Buffardi
    • Thierry Leblanc
    • Bradford S. Hoppe
    • Frank G. Keller
    • Kara M. Kelly
    • Lisa Giulino-Roth
    • Judith Landman-Parker
    • Juan Shen
    • Pallavi Pillai
    • Rushdia Yusuf
    • Auke Beishuizen

Biology and microenvironment

Selected for Oral Presentation

  • Show Details

    T025 (T025) Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classical Hodgkin lymphoma

    • Kristiina Karihtala
    • Suvi-Katri Leivonen
    • Teijo Pellinen
    • Marja-Liisa Karjalainen-Lindsberg
    • Tomohiro Aoki
    • Christian Steidl
    • Sirpa M. Leppä
  • Show Details

    T026 (T026) Circulating tumor DNA sequencing facilitates biological classification and individualized risk stratification in patients with Hodgkin lymphoma

    • Jan-Michel Heger
    • Laman Mammadova
    • Julia Mattlener
    • Sophia Sobesky
    • Melita Cirillo
    • Janine Altmüller
    • Elisabeth Kirst
    • Sarah Reinke
    • Wolfram Klapper
    • Paul J. Bröckelmann
    • Justin Ferdinandus
    • Helen Kaul
    • Gundolf Schneider
    • Jessica Schneider
    • Julia Katharina Schleifenbaum
    • Roland T. Ullrich
    • Max Freihammer
    • Sabine Awerkiew
    • Mia Lohmann
    • Florian Klein
    • Peter Nürnberg
    • Michael Hallek
    • Davide Rossi
    • Christine Mauz-Körholz
    • Stefan Gattenlöhner
    • Andreas Bräuninger
    • Peter Borchmann
    • Bastian von Tresckow
    • Sven Borchmann
  • Show Details

    T027 (T027) Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma

    • Ajay Subramanian
    • Shengqin Su
    • Jamie E. Flerlage
    • Stefan K. Alig
    • Sheren Younes
    • Lianna Marks
    • Chelsea Pinnix
    • Francisco Vega
    • Raphael E. Steiner
    • Priya Kumar
    • Heidi Mocikova
    • Alice Sykorova
    • Vit Prochazka
    • Cristiane Milito
    • Pamela B. Allen
    • Darina Paulino
    • Alan Ramsay
    • Timothy Flerlage
    • Monica Palese
    • Robert West
    • ChunFang Zhu
    • Joseph Schroers-Martin
    • Troy Noordenbos
    • Natalie Park
    • Anusha Kalbasi
    • Everett Moding
    • Aaron Newman
    • Ranjana H. Advani
    • Richard Hoppe
    • Maximilian Diehn
    • Yaso Natkunam
    • Ash A. Alizadeh
    • Michael Binkley
  • Show Details

    T028 (T028) Award winning Multi-Dimensional Profiling Unveils Distinct Molecular Subtypes in Classic Hodgkin Lymphoma

    • Tomohiro Aoki
    • Gerben Duns
    • Shinya Rai
    • Andrew Lytle
    • Yifan Yin
    • Aixiang Jiang
    • Stefan K. Alig
    • Mohammad Shahrokh Esfahani
    • Clementine Sarkozy
    • Stacy Hung
    • Katy Milne
    • Adele Telenius
    • Makoto Kishida
    • Michael Li
    • Luke O` Brien
    • Celia Strong
    • Talia Goodyear
    • Juan Patino Rangel
    • Michael Hong
    • Shaocheng Wu
    • Katsuyoshi Takata
    • Tomoko Miyata-Takata
    • Merrill Boyle
    • Susana Ben-Neriah
    • Andrew P. Weng
    • Andrew Roth
    • Michael Crump
    • John Kuruvilla
    • Anca Prica
    • Robert Kridel
    • Brad H. Nelson
    • Pedro Farinha
    • Ash A. Alizadeh
    • Kerry J. Savage
    • David W. Scott
    • Christian Steidl

Posters

  • Show Details

    P029 (P029) A novel in vitro model to study the effect of PD1 inhibition in Hodgkin Lymphoma at a molecular level

    • Rodrigo Martinez Alcala
    • Yajie Lei
    • Lydia Visser
    • Arjan Diepstra
    • Johanna Veldman
  • Show Details

    P030 (P030) Cell-Free DNA as Potential Prognosticator and Tracking Tool in Classic Hodgkin Lymphoma: Molecular Profiling and Clinical Correlations.

    • Nick Veltmaat
    • Geok Wee Tan
    • Yujie Zhong
    • Sophie Teesink
    • Martijn Terpstra
    • Johanna Bult
    • Marcel Nijland
    • Joost Kluiver
    • Arjan Diepstra
    • Anke van den Berg
    • Wouter J. Plattel
  • Show Details

    P031 (P031) Characteristics and outcomes of patients with Hodgkins Lymphoma with Paraneoplastic manifestations

    • Charanpreet Singh
    • Lekshmon K S
    • Arihant Jain
    • Alka Khadwal
    • Amanjit Bal
    • Radhika Srinivasan
    • Rajender K Basher
    • Pankaj Malhotra
    • Gaurav Prakash
  • Show Details

    P032 (P032) CK2 FAVORS T-CELL CHEMOTAXIS THROUGHT THE RELEASE OF SOLUBLE FACTORS BY HODGKIN AND REED–STERNBERG CELLS

    • Andrea Visentin
    • Federica Frezzato
    • Guido Capasso
    • Nayla Mouawad
    • Maria Castronuovo
    • Alessandro Cellini
    • Francesco Angotzi
    • Andrea Serafin
    • Chiara Adele Cavarretta
    • Valeria Ruocco
    • Arianna Bevilacqua
    • Sabrina Manni
    • Monica Facco
    • Federico Scarmozzino
    • Marco Pizzi
    • Fabrizio Vianello
    • Francesco Piazza
    • Livio Trentin
  • Show Details

    P033 (P033) Final analysis of correlation between serum TARC concentration and MTV,TLG in a cohort of Classical Hodgkin lymphoma during first line treatment.

    • Benedetta Sordi
    • Ciceri Manuel
    • Leonardo Signori
    • Elisabetta Abenavoli
    • Aurora Lombardo
    • Ilaria Romano
    • Marianna Palazzo
    • Giacomo Coltro
    • Michela Zizza
    • Fabiana Pancani
    • Luca Nassi
    • Benedetta Puccini
  • Show Details

    P034 (P034) Gene Expression Signature Reveals a Protective Role of B-cells in the Progression of classical Hodgkin Lymphoma patients

    • Benedetta Donati
    • Tanja Lazic
    • Maria Elena Nizzoli
    • Alberto Bavieri
    • Rexhep Durmo
    • Riccardo Valli
    • Attilio Gennaro
    • Cristian Ascione
    • Alessia Ruffini
    • Stefano Pozzi
    • Annibale Versari
    • Francesco Merli
    • Alessia Ciarrocchi
    • Stefano Luminari
  • Show Details

    P035 (P035) Histological Grading in Nodular Sclerosis Classical Hodgkin Lymphoma Identifies a Subgroup of Patients with Higher Early Response Rates and Better Prognosis in the Contemporary Treatment Era

    • Alessandro Cellini
    • Federico Scarmozzino
    • Chiara Adele Cavarretta
    • Francesco Angotzi
    • Valeria Ruocco
    • Andrea Serafin
    • Nicolò Danesin
    • Michele Gregianin
    • Stefania Vio
    • Filippo Crimì
    • Federica Vianello
    • Francesco Piazza
    • Marco Pizzi
    • Livio Trentin
    • Andrea Visentin
  • Show Details

    P036 (P036) Immune landscape associated with response to brentuximab vedotin with ipilimumab and/or nivolumab in relapsed Hodgkin lymphoma in E4412 Phase 1

    • Catherine Diefenbach
    • Edgar Gonzalez-Kozlova
    • Diane Marie Del Valle
    • Hsin-Hui Huang
    • Opeyemi Jegede
    • Vanessa Barcessat
    • Kevin Tuballes
    • Geoffrey Kelly
    • Manishkumar Patel
    • Hui Xie
    • Jocelyn Harris
    • Kimberly Argueta
    • Kai Nie
    • Radim Moravec
    • Jen Altreuter
    • Dzifa Yawa Duose
    • Brad S. Kahl
    • Stephen M. Ansell
    • Jocye Yu
    • Ethan Cerami
    • James Lindsay
    • Ignacio Wistuba
    • Seunghee Kim-Schulze
    • Sacha Gnjatic
  • Show Details

    P037 (P037) Impact of Clonal hematopoiesis of indeterminate potential in classical Hodgkin lymphoma

    • Caroline Hesselager
    • Peter Hollander
    • Ann-Sofie Johansson
    • Johan Linderoth
    • Gunilla Enblad
    • Simone Weström
    • Daniel Eriksson
    • Arielle R Munters
    • Daniel Molin
    • Panagiotis Baliakas
    • Rose-Marie Amini
  • Show Details

    P038 (P038) Molecular pathogenesis of Hodgkin lymphoma

    • Lilian Beeck
    • Bettina Budeus
    • Markus Schneider
    • Navid Farsijani
    • Julia Bein
    • Sylvia Hartmann
    • Martin-Leo Hansmann
    • Ralf Küppers
  • Show Details

    P039 (P039) Award winning New understanding of oncogenic mechanisms in classical Hodgkin lymphoma

    • Maria Cristina Pirosa
    • Matin Salehi
    • Alessio Bruscaggin
    • Lodovico Terzi di Bergamo
    • Federico Jauk
    • Gabriela Forestieri
    • Simone Bocchetta
    • Deborah Piffaretti
    • Riccardo Moia
    • Vanessa Cristaldi
    • Martina di Trani
    • Georgia Alice Galimberti
    • Katia Pini
    • Valeria Spina
    • Claudia Giordano
    • Adalgisa Condoluci
    • Salvatore Annunziata
    • Fabrizio Bergesio
    • Renzo Boldorini
    • Eugenio Borsatti
    • Pietro Bulian
    • Stephane Chauvie
    • Marco Cuzzocrea
    • Bernhard Gerber
    • Michał Kurlapski
    • Luigi Maria Larocca
    • Andrea Rinaldi
    • Marcello Rodari
    • Grzegorz Romanowicz
    • Gian Mauro Sacchetti
    • Anastasios Stathis
    • Georg Stüssi
    • Ilaria Zangrilli
    • Eleonora Calabretta
    • Francesco Corrado
    • Antonio Pinto
    • Luca Mazzucchelli
    • Valter Gattei
    • Jan Maciej Zaucha
    • Armando Santoro
    • Stefan Hohaus
    • Franco Cavalli
    • Emanuele Zucca
    • Gianluca Gaidano
    • Carmelo Carlo‐Stella
    • Alexandar Tzankov
    • Luca Ceriani
    • Davide Rossi
  • Show Details

    P040 (P040) Plasma proteins and Hodgkin's lymphoma: Proteome-wide Mendelian randomization and colocalization analyses

    • Tao Pan
    • Jiyue Zhang
    • Xiaomin Wang
    • Yuqin Song
  • Show Details

    P041 (P041) Proteomic profile in classical Hodgkin Lymphoma patients with high inflammation

    • Jeremia Collin
    • Ragnhild Risebro
    • Johan Mattsson Ulfstedt
    • Emma Pettersson
    • Mats Hellström
    • Ingrid Glimelius
    • Mattias Berglund
    • Gunilla Enblad
    • Eva Freyhult
    • Daniel Molin
  • Show Details

    P042 (P042) Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity

    • Maja Dam Andersen
    • Katharina Wolter
    • Marie Hairing Enemark
    • Kristina Lystlund Lauridsen
    • Stephen Jacques Hamilton-Dutoit
    • Jørn Starklint
    • Francesco d'Amore
    • Maja Ludvigsen
    • Bent Honoré
    • Peter Kamper
  • Show Details

    P043 (P043) Award winning SPATIAL ORGANIZATION OF THE TUMOR MICROENVIRONMENT IN NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA AND T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: INSIGHTS FROM A PILOT COHORT STUDY

    • Ilja Kalashnikov
    • Kerttu Kalander
    • Ada Junquera
    • Matias Autio
    • Suvi-Katri Leivonen
    • Johannes Dunkel
    • Anniina Färkkilä
    • Sirpa M. Leppä
  • Show Details

    P044 (P044) Sulforaphane, a Natural Compound, Inhibits Cell Growth and Promotes NK Cell-Mediated Anti-Tumor Immune Responses Through cGAS-STING Pathway in Classical Hodgkin Lymphoma

    • Ioanna Xagoraris
    • Ying Yang
    • Erofili Bougka
    • Dora Trogrlic
    • Persa Xyderou
    • Konstantina Stathopoulou
    • Christina An Bihn Nordentoft
    • Nikolas Herold
    • Andreas Lundqvist
    • Georgios Z. Rassidakis
  • Show Details

    P045 (P045) T-cell diversity and exclusion of blood-derived clonally expanded T-cells in the tumor microenvironment of classical Hodgkin Lymphoma

    • Nicole Seifert
    • Sarah Reinke
    • Johanna Grund
    • Berit Müller-Meinhard
    • Julia Richter
    • Thorsten Heilmann
    • Hans Schlößer
    • Michaela Biehl-Kotrova
    • Monika Brüggemann
    • Peter Borchmann
    • Paul J. Bröckelmann
    • Michael Altenbuchinger
    • Wolfram Klapper
  • Show Details

    P046 (P046) Transcriptional reprogramming by mutated IRF4 in lymphoma

    • Nikolai Schleussner
    • Pierre Cauchy
    • Vedran Franke
    • Maciej Giefing
    • Oriol Fornes
    • Naveen Vankadari
    • Salam Assi
    • Mariantonia Costanza
    • Marc A. Weniger
    • Altuna Akalin
    • Ioannis Anagnostopoulos
    • Thomas Bukur
    • Marco Casarotto
    • Frederik Damm
    • Oliver Daumke
    • Benjamin Edginton-White
    • Christof Gebhardt
    • Michael Grau
    • Stephan Grunwald
    • Martin-Leo Hansmann
    • Sylvia Hartmann
    • Lionel Huber
    • Eva Kärgel
    • Simone Lusatis
    • Daniel Nörenberg
    • Nadine Obier
    • Ulrich Pannicke
    • Anja Pfaus
    • Anja Reisser
    • Andreas Rosenwald
    • Klaus Schwarz
    • Srinivasan Sundararaj
    • Andre Weilemann
    • Wiebke Winkler
    • Wendan Xu
    • Georg Lenz
    • Klaus Rajewsky
    • Wyeth Wassermann
    • Peter Cockerill
    • Claus Scheidereit
    • Reiner Siebert
    • Ralf Küppers
    • Rudolf Grosschedl
    • Martin Janz
    • Constanze Bonifer
    • Stephan Mathas
  • Show Details

    P047 (P047) Trial in Progress: Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (NAHL)

    • Harsh Shah
    • Boyu Hu
    • Ken Boucher
    • Deborah Stephens
  • Show Details

    P048 (P048) Tumor-associated macrophages correlate with skeletal involvement in classic Hodgkin lymphoma

    • Maja Dam Andersen
    • Katharina Wolter
    • Marie Hairing Enemark
    • Mette Abildgaard Pedersen
    • Lars Christian Gormsen
    • Kristina Lystlund Lauridsen
    • Jørn Starklint
    • Stephen Jacques Hamilton-Dutoit
    • Francesco d'Amore
    • Maja Ludvigsen
    • Peter Kamper

Older patients

Selected for Oral Presentation

  • Show Details

    T074 (T074) A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent

    • Kjersti Lia
    • Rasmus Rask KJ
    • Bente L. Wold
    • Øystein Fluge
    • Unn-Merete Fagerli
    • Hanne Bersvendsen
    • Idun B.Bø
    • Sameer Bhargava
    • Alexander Fosså
  • Show Details

    T075 (T075) Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023

    • Aisling Barrett
    • Zhe Wang
    • Andrew Challenger
    • Sarah Darby
    • John Broggio
    • David Cutter
  • Show Details

    T076 (T076) Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial

    • Justin Ferdinandus
    • Helen Kaul
    • Alexander Fosså
    • Andreas Hüttmann
    • Felix Keil
    • Yon-Dschun Ko
    • Felicitas Hitz
    • Stefanie Kreissl
    • Michael Fuchs
    • Dennis A. Eichenauer
    • Bastian von Tresckow
    • Peter Borchmann
    • Paul J. Bröckelmann
  • Show Details

    T077 (T077) Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥60 years with advanced stage classical Hodgkin lymphoma (cHL) enrolled on SWOG S1826

    • Sarah Rutherford
    • Hongli Li
    • Alex F. Herrera
    • Michael LeBlanc
    • Sairah Ahmed
    • Kelly Davison
    • Carla Casulo
    • Nancy L. Bartlett
    • Joseph Tuscano
    • Brian Hess
    • Pallawi Torka
    • Pankaj Kumar
    • Ryan Jacobs
    • Joo Song
    • Sharon M. Castellino
    • Brad S. Kahl
    • John Leonard
    • Sonali Smith
    • Jonathan W. Friedberg
    • Andrew Evens

Posters

  • Show Details

    P078 (P078) ‘ACOPP’ chemotherapy for older and less fit patients with Hodgkin lymphoma – a multicentre, retrospective study

    • Matthew Wilson
    • Euan Haynes
    • Katrina Parsons
    • David Hopkins
    • Elizabeth Robertson
    • Graeme Ferguson
    • Daire Quinn
    • Jim Murray
    • Wendy Osborne
    • Mike Leach
    • Pam McKay
  • Show Details

    P079 (P079) Anthracycline-based therapy for elderly HL patients : a retrospective series from a single South Italy center.

    • Vittoria Tarantino
    • Marika Porrazzo
    • Monica Maria Agata Leone
    • Ernesto Torretta
    • Antonino Mulè
    • Caterina PATTI
    • Luca Castagna
  • Show Details

    P080 (P080) Brentuximab vedotin monotherapy is a feasible and effective treatment in elderly and frail patients with classical Hodgkin lymphoma: Results of the prospective GHSG-NLG phase II BVB trial.

    • Alexander Fosså
    • Daniel Molin
    • Paul J. Bröckelmann
    • Gundolf Schneider
    • Ulf Schnetzke
    • Johan Linderoth
    • Peter Kamper
    • Sirpa M. Leppä
    • Julia Meissner
    • Valdete Schaub
    • Kjersti Lia
    • Michael Fuchs
    • Peter Borchmann
    • Boris Böll
  • Show Details

    P081 (P081) Brentuximab vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II BVB Trial

    • Paul J. Bröckelmann
    • Boris Böll
    • Daniel Molin
    • Gundolf Schneider
    • Sirpa M. Leppä
    • Julia Meissner
    • Peter Kamper
    • Martin Hutchings
    • Jacob Haaber Christensen
    • Ulf Schnetzke
    • Michael Fuchs
    • Dennis A. Eichenauer
    • Bastian von Tresckow
    • Helen Kaul
    • Peter Borchmann
    • Alexander Fossa
  • Show Details

    P082 (P082) Elderly Classical Hodgkin Lymphoma: Croatian Cooperative Group for Hematological Diseases (KroHem) Experience

    • Ida Hude Dragičević
    • Ida Ivek
    • Sandra Bašić-Kinda
    • Karla Mišura Jakobac
    • Marija Ivić Čikara
    • Marija Petrić
    • Vlatka Periša
    • Ivana Vučinić Ljubičić
    • Ivana Sušac Zrna
    • Ivan Krečak
    • Dina Mokwa
    • Tomislav Čolak
    • Barbara Dreta
    • Dino Dujmović
    • Igor Aurer
  • Show Details

    P083 (P083) Hodgkin Lymphoma in Older Patients (HoOP)- A European Retrospective Study

    • Aisling Barrett
    • Amy A. Kirkwood
    • Cathy Burton
    • Ruth Clifford
    • Robert Henderson
    • Pam McKay
    • Wendy Osborne
    • Nimish Shah
    • Graham P. Collins
  • Show Details

    P084 (P084) Patients over the age of 60 years treated with Hodgkin's lymphoma at our Clinic

    • Dávid Tóthfalusi
    • László Imre Pinczés
    • Boglárka Dobó
    • Árpád Illés
    • Zsófia Miltényi
  • Show Details

    P085 (P085) Treatment Efficacy, Overall Survival, and Disease-Free Survival in Elderly versus Younger Patients with Hodgkin's Lymphoma: A Decade of Experience at a Latin American Reference Hospital

    • Gerardo Santiago Jimenez
    • Alonso Hernández Company
    • Karen Torres Castellanos
    • Gilberto Israel Barranco Lampón
    • Juan Francisco Zazueta Pozos
    • Daniela de Jesús Pérez Sámano
    • Emmanuel Martínez Moreno
    • Carlos Martínez Murillo
    • Adán Germán Gallardo
    • Omar Ramos Peñafiel Christian

Advanced stages

Selected for Oral Presentation

  • Show Details

    T001 (T001) Award winning 2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma

    • Alex F. Herrera
    • Michael LeBlanc
    • Sharon M. Castellino
    • Hongli Li
    • Sarah Rutherford
    • Andrew Evens
    • Kelly Davison
    • Angela Punnett
    • Susan K. Parsons
    • Sairah Ahmed
    • Carla Casulo
    • Nancy L. Bartlett
    • Joseph Tuscano
    • Matthew Mei
    • Brian Hess
    • Ryan Jacobs
    • Hayder Saeed
    • Pallawi Torka
    • Boyu Hu
    • Craig H. Moskowitz
    • Supreet Kaur
    • Gaurav Goyal
    • Christopher Forlenza
    • Andrew Doan
    • Adam Lamble
    • Pankaj Kumar
    • Saeeda Chowdury
    • Brett Brinker
    • Namita Sharma
    • Avina Singh
    • Kristie Blum
    • Anamarija Perry
    • Alexandra Kovach
    • David Hodgson
    • Louis Constine
    • Lale Kostakoglu
    • Anca Prica
    • Hildy Dillon
    • Richard F. Little
    • Margaret A. Shipp
    • Michael Crump
    • Brad S. Kahl
    • John Leonard
    • Sonali Smith
    • Kara M. Kelly
    • Jonathan W. Friedberg
  • Show Details

    T002 (T002) Development and application of a validated MRD assay in Hodgkin Lymphoma

    • Julia Mattlener
    • Jessica Schneider
    • Julia Katharina Schleifenbaum
    • Max Freihammer
    • Olivia Käsgen
    • Kerstin Becker
    • Hodgkin Lymphoma MRD Consortium
    • Justin Ferdinandus
    • Helen Kaul
    • Gundolf Schneider
    • Peter Borchmann
    • Jan-Michel Heger
    • Sven Borchmann
  • Show Details

    T003 (T003) EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS

    • Martin Hutchings
    • Sophie Teesink
    • Anna Sureda-Balari
    • Susana Carvalho
    • Andrej Vranovsky
    • Walter Noordzij
    • Annika Loft
    • Anne I. J. Aarens
    • Wendy Stevens
    • Arjan Diepstra
    • Berthe M.P. Aleman
    • Sherida Woei-A-Jin
    • Maria Viguria
    • Kirsten Saevels
    • Liane Te Boome
    • Sanne Tonino
    • Paul Meijnders
    • Eva Domingo-Domènech
    • Caroline Hasselbalch Riley
    • Sarah Nuyens
    • Cedric Mallien
    • Ward Sents
    • Emanuel Buhrer
    • Catherine Fortpied
    • Wouter J. Plattel
  • Show Details

    T004 (T004) Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials

    • Justin Ferdinandus
    • Helen Kaul
    • Gundolf Schneider
    • Michael Fuchs
    • Hans-Theodor Eich
    • Johannes Rosenbrock
    • Christian Baues
    • Katrin S. Roth
    • Alexander Drzezga
    • Lutz van Heek
    • Markus Dietlein
    • Peter Borchmann
    • Carsten Kobe

Posters

  • Show Details

    P005 (P005) Accuracy of Ann Arbor Stage Assignment Based on PET/CT Reports Using a Large Language Model in Hodgkin Lymphoma Patients

    • Conrad-Amadeus Voltin
    • Jonathan Kottlors
    • Peter Borchmann
    • Philipp Gödel
    • Alexander Drzezga
    • Markus Dietlein
    • Thomas Dratsch
  • Show Details

    P006 (P006) Adaptation of a PET-based treatment strategy and outcomes of patients with Advanced Hodgkins Lymphoma in resource constrained settings

    • Charanpreet Singh
    • K. S. Lekshmon
    • Arihant Jain
    • Alka Khadwal
    • Amanjit Bal
    • Radhika Srinivasan
    • Rajender K Basher
    • Pankaj Malhotra
    • Gaurav Prakash
  • Show Details

    P007 (P007) Are Four Cycles of BEACOPP Escalated Sufficient for Patients with Advanced Hodgkin Lymphoma and PET-2 Deauville Score 3?

    • Heidi Mocikova
    • Jana Markova
    • Lubica Gaherova
    • Maria Maco
    • Eva Maule
    • Jozef Michalka
    • Andrea Janikova
    • Alice Sykorova
    • Pavla Stepankova
    • Katarina Hradska
    • Juraj Duras
    • Alexandra Kredatusova
    • Vit Prochazka
    • Zdenek Kral
    • Tomas Kozak
  • Show Details

    P008 (P008) Brentuximab Vedotin (BV) Exposure and Long-Term Efficacy Analysis in Patients With Classical Hodgkin’s Lymphoma (cHL): Analysis of Phase 3 ECHELON-1 Study

    • Zufei Zhang
    • Daping Zhang
    • Fei Jie
    • Keenan Fenton
    • Evelyn Rustia
    • Consuelo Glenn
    • Michelle Fanale
    • Tatyana Feldman
    • Stephen M. Ansell
    • Yen-Lin Chia
  • Show Details

    P009 (P009) Brentuximab vedotin plus chemotherapy in patients with previously untreated Stage III/IV classical Hodgkin lymphoma: seven-year overall survival analysis from ECHELON-1

    • Martin Hutchings
    • Stephen M. Ansell
    • David J. Straus
    • Joseph M. Connors
    • Wojciech Jurczak
    • Won-Seog Kim
    • Andrea Gallamini
    • Radhakrishnan Ramchandren
    • Jonathan W. Friedberg
    • Ranjana H. Advani
    • Andrew M. Evens
    • Kerry J. Savage
    • Hyeon-Seok Eom
    • Tatyana Feldman
    • Jeremy S. Abramson
    • Cassie Dong
    • Bipin Savani
    • Athanasios Zomas
    • Keenan Fenton
    • John Radford
  • Show Details

    P010 (P010) Clinico-pathological correlation in patients with positive end of treatment PET after pembrolizumab + AVD for untreated classic Hodgkin lymphoma

    • Ryan Lynch
    • Kikkeri Naresh
    • Ridvan Demirci
    • Delphine Chen
    • Chaitra Ujjani
    • Christina Poh
    • Edus H. Warren
    • Stephen Smith
    • Mazyar Shadman
    • Brian Till
    • Vikram M. Raghunathan
    • Yolanda Tseng
    • Ajay K. Gopal
  • Show Details

    P011 (P011) Data Collaborations Accelerate Pediatric Hodgkin Lymphoma Research Through NODAL

    • Flerlage Jamie
    • Suzi Birz
    • Sharon M. Castellino
    • Tara O. Henderson
    • John Lucas
    • Lindsay A. Renfro
    • Yiwang Zhou
    • Samuel Volchenboum
    • Brian Furner
    • Michael Watkins
    • Kara M. Kelly
  • Show Details

    P012 (P012) Exploring the capability of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index to predict the lack of an early complete metabolic response in a multicentric Italian cohort

    • Alessandro Cellini
    • Giovanni Manfredi Assanto
    • Alessandra Romano
    • Gabriella Santuccio
    • Candida Vitale
    • Maria Chiara Montalbano
    • Chiara Adele Cavarretta
    • Francesco Angotzi
    • Valeria Ruocco
    • Andrea Serafin
    • Nicolò Danesin
    • Marta Coscia
    • Francesco Di Raimondo
    • Ilaria Del Giudice
    • Francesco Piazza
    • Livio Trentin
    • Andrea Visentin
  • Show Details

    P013 (P013) High rates of undetectable MRD by PhasED-Seq on interim and end of treatment timepoints in untreated advanced stage CHL treated with pembrolizumab + AVD

    • Ryan Lynch
    • Stefan K. Alig
    • Chaitra Ujjani
    • Christina Poh
    • Edus H. Warren
    • Stephen Smith
    • Mazyar Shadman
    • Brian Till
    • Vikram M. Raghunathan
    • Yolanda Tseng
    • Susan Ottemiller
    • Bonnie Joy
    • Melissa Fessel
    • Hongyan Du
    • Jackie Vandermeer
    • Alyssa Kelly
    • Heather Rasmussen
    • Jenna Voutsinas
    • Ash A. Alizadeh
    • Ajay K. Gopal
  • Show Details

    P014 (P014) Hodgkins Lymphoma in Latin American patients: Ten years experience in a reference center in Mexico.

    • Alonso Hernández Company
    • Gerardo Santiago Jiménez
    • Karen Torres Castellanos
    • Gilberto Israel Barranco Lampón
    • Juan Francisco Zazueta Pozos
    • Daniela de Jesús Pérez Sámano
    • Emmanuel Martínez Moreno
    • Adán Germán Gallardo Rodríguez
    • Carlos Martínez Murillo
    • Omar Ramos Peñafiel Christian
  • Show Details

    P015 (P015) Identification of Risk Categories and Stratification from the Advanced-Stage Hodgkin Lymphoma (AS-HL) International Prognostic Index (A-HIPI) Model

    • Matthew Maurer
    • Susan K. Parsons
    • Jenica Upshaw
    • Angie Mae Rodday
    • Jonathan W. Friedberg
    • Andrea Gallamini
    • Massimo Federico
    • Eliza Hawkes
    • David Hodgson
    • Peter Johnson
    • Eric Mou
    • Kerry Savage
    • Pier Luigi Zinzani
    • Andrew Evens
  • Show Details

    P016 (P016) Implementing BrECADD for the treatment of adult patients with newly diagnosed advanced stage classical Hodgkin’s lymphoma (AS-cHL). A single center experience

    • Athanasios Gakopoulos
    • Chara Giatra
    • Michael Panousieris
    • Sotiris Bristogiannis
    • Athanasia Apsemidou
    • Antonia Mitkou
    • Christos Masaoutis
    • Ioannis Baltadakis
    • Maria Bouzani
  • Show Details

    P017 (P017) INDIRECT CLINICAL TRIALS COMPARISONS OF TREATMENTS FOR ADVANCED-STAGED HODGKIN LYMPHOMA WITH INDIVIDUAL PATIENT DATA EXTRACTION.

    • Andrea Visentin
    • Alessandro Cellini
    • Francesco Angotzi
    • Valeria Ruocco
    • Andrea Serafin
    • Nicolò Danesin
    • Arianna Bevilacqua
    • Chiara Adele Cavarretta
    • Francesco Piazza
    • Livio Trentin
  • Show Details

    P018 (P018) Lower doses of dacarbazine as a safer strategy in Hodgkin Lymphoma’s intensive treatment protocol (modified escalated BEACODD): preliminary retrospective analysis of a single and public center in Brazil.

    • Arthur Gomes Oliveira Braga
    • Larissa Hilario Dulley
    • Guilherme Garcia Rodrigues
    • Sergio Costa Fortier
    • Carlos Sergio Chiattone
    • Talita Maira Bueno da Silveira
  • Show Details

    P019 (P019) Pembrolizumab + AVD in classic Hodgkin lymphoma: Low rates of febrile neutropenia despite frequent grade 4 neutropenia

    • Thomas Kuczmarski
    • Chaitra Ujjani
    • Christina Poh
    • Edus H. Warren
    • Stephen Smith
    • Mazyar Shadman
    • Brian Till
    • Vikram M. Raghunathan
    • Yolanda Tseng
    • Hongyan Du
    • Jackie Vandermeer
    • Alyssa Kelly
    • Heather Rasmussen
    • Jenna Voutsinas
    • Ajay K. Gopal
    • Ryan Lynch
  • Show Details

    P020 (P020) Real-life experience with BV-AVD combination in advanced stage classical Hodgkin Lymphoma: A multicenter study from Greece

    • Athanasios Liaskas
    • Maria Angelopoulou
    • Pinelopi Vryttia
    • Evgenia Verrou
    • Alexia Piperidou
    • Maria-Aikaterini Lefaki
    • Angeliki Georgopoulou
    • Alexandros Machairas
    • Dionisios Stoumbos
    • Georgia Kaiafa
    • Anastasia Sioni
    • Nikolaos Kanellias
    • Maria Arapaki
    • Elianna Constantinou
    • Dimitrios Gogos
    • Marina Siakantari
    • Eirini Katodritou
    • Panayiotis Panayiotidis
    • Sotirios Papageorgiou
    • Theodoros Vassilakopoulos
  • Show Details

    P021 (P021) SERUM TARC COMBINED WITH FDG-PET IMAGING IMPROVES INTERIM RESPONSE EVALUATION IN CLASSIC HODGKIN LYMPHOMA: A RETROSPECTIVE ANALYSIS OF GERMAN HODGKIN STUDY GROUP HD16 AND HD18 TRIALS

    • Wouter J. Plattel
    • Janina Jablonski
    • Mia Lohmann
    • Bastian Von Tresckow
    • Anna Sureda
    • Michiel Pegtel
    • Josée M. Zijlstra
    • John Radford
    • Bart-Jan Kroesen
    • Lydia Visser
    • Michael Fuchs
    • Peter Borchmann
    • Arjan Diepstra
    • Sven Borchmann
  • Show Details

    P022 (P022) TREATMENT OF CLASSICAL HODGKIN'S LYMPHOMA (cHL) WITH BRENDUXIMAB VEDOTIN - DOXORUBICIN – VINBLASTINE – DACARBAZINE (BV-AVD). ONE CENTER’S EXPERIENCE

    • Chara Giatra
    • Andri Polyviou
    • Kyriaki Kontitsi
    • Tatiana Tzenou
    • Michael Panousieris
    • Vasiliki Babali
    • Athanasia Apsemidou
    • Sotiris Bristogiannis
    • Athanasios Gakopoulos
    • Evridiki Theodorou
    • George Kanellis
    • Ioannis Baltadakis
    • Stavros Gigantes
    • Maria Bouzani
  • Show Details

    P023 (P023) Trial In Progress: CTEP 10590, NORM: Nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab

    • Raphael E. Steiner
    • Hun Ju Lee
    • Michael Green
    • Ruitao Lin
    • Chelsea Pinnix
    • Alison Moskowitz
    • Joachim Yahalom
    • Dai Chihara
  • Show Details

    P024 (P024) Trial in Progress: PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory (R/R) Hematologic Malignancies

    • Tae Min Kim
    • Katherine Lewis
    • Juan Alderuccio
    • Hun Ju Lee
    • Enrico Derenzini
    • Pier Luigi Zinzani
    • Marco Ladetto
    • Elizabeth H. Phillips
    • Herve Ghesquieres
    • François Lemonnier
    • Franck Morschhauser
    • Anna Sureda-Balari
    • Antonia Rodriguez Izquierdo
    • Peter Borchmann
    • Matthew Weinstock
    • Jakub Svoboda
    • Emma Dean
    • Jelena Urosevic
    • Stefanie Meyer
    • Robert Chen
    • Ting Yu
    • Ruben Reyes
    • Kaitlyn Beyfuss
    • Graham P. Collins

Living beyond lymphoma

Selected for Oral Presentation

  • Show Details

    T062 (T062) A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations

    • Michael Oertel
    • Priska Hölscher
    • Dominik A. Hering
    • Christopher Kittel
    • Michael Fuchs
    • Niklas B. Pepper
    • Stefan Lerch
    • Uwe Haverkamp
    • Peter Borchmann
    • Hans T. Eich
  • Show Details

    T063 (T063) Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

    • Sidsel J. Juul
    • Sára Rossetti
    • Berthe M.P. Aleman
    • Flora E. van Leeuwen
    • Marleen A.E. van der Kaaij
    • Francesco Giusti
    • Paul Meijnders
    • John M.M. Raemaekers
    • Hanneke C. Kluin-Nelemans
    • Michele Spina
    • Daphne Krzisch
    • Camille Bigenwald
    • Aspasia Stamatoullas
    • Marc André
    • Wouter J. Plattel
    • Martin Hutchings
    • Maja V. Maraldo
  • Show Details

    T064 (T064) Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors

    • Zeinab Salah
    • Mustafa Selim
    • Nesreen Ali
    • Antoine Abdelmassih
    • Mohammed Mosaad Soliman
    • Nahla M El Nabarawy
    • Hany Hussein
    • Doaa Mohamed Albeltagi
    • Iman Sidhom

Posters

  • Show Details

    P065 (P065) An exploration of patient specific and systemic delays as part of the diagnostic odyssey in patients with Hodgkin lymphoma- an analysis of the Lymphoma Coalition’s 2022 Global Patient Survey

    • Steve Kalloger
    • Amanda Watson
    • Shawn Sajkowski
    • Lorna Warwick
  • Show Details

    P066 (P066) Analysis of fetal dose exposure by modern radiation therapy in pregnant patients with supradiaphragmatic Hodgkin lymphoma - A phantom-based simulation

    • Michael Oertel
    • Gina Smeets
    • Isabel Vogt
    • Heidi Wolters
    • Christopher Kittel
    • Dominik A. Hering
    • Burkhard Greve
    • Uwe Haverkamp
    • Hans T. Eich
  • Show Details

    P067 (P067) Excellent outcomes with low intensity treatment based on age and stage in children and adults with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): a 10yr retrospective analysis of patients from 8 UK centres.

    • Thomas Jackson
    • Amy A. Kirkwood
    • Kushani Ediriwickrema
    • Satyen Gohil
    • Xiao-Yin Zhang
    • Graham P. Collins
    • Georgina Hall
    • David Hopkins
    • Pamela McKay
    • Ananth Shankar
    • Valeria Fiaccadori
  • Show Details

    P068 (P068) Hodgkin’s Lymphoma in Armenia: Diagnostic Delays and the Unintended Benefits of COVID-19 Screening

    • Lusine Sahakyan
    • Diana Soghomonyan
    • Astghik Voskanyan
    • Arev Stepanyan
    • Lusine Stepanyan
    • Marina Melik-Andreasyan
    • Levon Evoyan
    • Miranush Saaryan
  • Show Details

    P069 (P069) Male sex and longer time since Hodgkin lymphoma diagnosis are associated with non-attendance at survivorship clinics

    • Eline M.J. Lammers
    • Berthe M.P. Aleman
    • Michael Schaapveld
    • Josée M. Zijlstra
    • Cécile P.M. Janus
    • Roel J. de Weijer
    • Maaike G.A. Schippers
    • Rinske S. Boersma
    • Saskia S. Gommers
    • Mirjam Kappert
    • Flora E. van Leeuwen
    • Annelies Nijdam
  • Show Details

    P070 (P070) Management and Follow-Up of Pregnancy in Patients Diagnosed with Hodgkin's Lymphoma

    • Norayr Ghukasyan
    • Poghosyan Andranik
    • Gharibyan Edita
    • Danielyan Lusine
    • Sahakyan Lusine
    • Marina Melik-Andreasyan
    • Heghine Khachatryan
  • Show Details

    P071 (P071) MyHodgkin MyHealth (MHMH): Mobile App for patient-entered data to collect long term follow up (LTFU) after Hodgkin Lymphoma (HL) treatment

    • Nicole Wong Doo
    • Janlyn Falconer
    • Gajan Kailainathan
    • Patrick E. Lawrence
    • Georgia Klemm
    • Nathan Chapman
    • Judith Trotman
  • Show Details

    P072 (P072) Study of long-term survivorship of lymphoma patients – a multicenter longitudinal study of return to work and quality of life (ALLY)

    • Ruth Elisa Eyl-Armbruster
    • Julia Wendler
    • Ramona Böttinger
    • Simone Neumaier
    • Antje Jensch
    • Markus Knott
    • Susanne Rössle
    • Nicola Giesen
    • Jessika Strentzsch
    • Veronika Schindler
    • Hans-Georg Kopp
    • Jochen Greiner
    • Claudio Denzlinger
    • Gerald Illerhaus
  • Show Details

    P073 (P073) The national Breast screening After Radiotherapy Dataset (BARD) identifies women in England at very high risk (VHR) of breast cancer (BC) following radiotherapy (RT) and ensures timely referral to the correct national screening pathway

    • John Radford
    • Joanna Williams
    • Elsita Payne
    • Kirstin Roberts
    • Jacquie Jenkins
    • Anne Mackie
    • Aislinn Macklin-Doherty
    • Anthony Swerdlow
    • Martin McCabe
    • Tanya Massey
    • Debbie Worthington
    • Natalie Yates-Bolton
    • Marianne Aznar
    • Richard Cowan
    • Sacha Howell

Relapsed and refractory

Selected for Oral Presentation

  • Show Details

    T104 (T104) Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.

    • Anna Sureda
    • Javier Núñez Céspedes
    • María José Terol Casterá
    • Francisca Hernández Mohedo
    • Eva Domingo-Domènech
    • Fátima de la Cruz Vicente
    • Miriam Moreno Velázquez
    • M. Elena Amutio Díaz
    • Ana Pilar González Rodríguez
    • Raúl Córdoba
    • Carmen Martínez Muñoz
    • Samuel Romero Domínguez
    • Mariana Bastos
    • Antonia Rodríguez Izquierdo
    • Javier Briones Meijide
    • Richard Greil
    • María Casanova
    • Araceli Rubio
    • Irit Avivi
    • Raquel del Campo García
    • Pilar Gómez
    • Theodoros Vassilakopoulos
    • Sandra Basic-Kinda
    • Sotirios Papageorgiou
    • Víctor Noriega
    • José Javier Sánchez Blanco
    • Blanca Sánchez
    • Izaskun Zeberio
    • Ramón García-Sanz
  • Show Details

    T105 (T105) Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients

    • Francesco Corrado
    • Eleonora Calabretta
    • Martina di Trani
    • Martina Sollini
    • Vanessa Cristaldi
    • Lodovico Terzi di Bergamo
    • Alessio Bruscaggin
    • Maria Cristina Pirosa
    • Marcello Viscovo
    • Stefania Bramanti
    • Arturo Chiti
    • Stefan Hohaus
    • Armando Santoro
    • Davide Rossi
    • Carmelo Carlo‐Stella
  • Show Details

    T106 (T106) Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

    • Alison Moskowitz
    • Gunjan Shah
    • Nivetha Ganesan
    • Helen Hancock
    • Theresa Davey
    • Tiffany Chang
    • Brittney Munayirji
    • Monifa Douglas
    • Alayna M. Santarosa
    • Alexander Boardman
    • Philip Caron
    • Kevin David
    • Zachary Epstein-Peterson
    • Lorenzo Falchi
    • Paola Ghione
    • Andrew Intlekofer
    • Paul Hamlin
    • Steven Horwitz
    • William Johnson
    • Anita Kumar
    • Jennifer Lue
    • Efrat Luttwak
    • Ariela Noy
    • Colette Owens
    • Maria Palomba
    • Gilles Salles
    • Raphael E. Steiner
    • Robert Stuver
    • Pallawi Torka
    • Santosha Vardhana
    • Andrew Zelenetz
    • Joachim Yahalom
    • Ahmet Dogan
    • Heiko Schoder
    • Craig H. Moskowitz

Posters

  • Show Details

    P107 (P107) A short course of nivolumab (N) followed by chemotherapy BGD and autologous transplantation (aHCT) as the salvage treatment for relapsed/refractory (r/r) Hodgkin Lymphoma (cHL) patients – the preliminary results of the N-BURGUND trial of PLRG

    • Jan Maciej Zaucha
    • Ewa Paszkiewicz-Kozik
    • Bogdan Małkowski
    • Michał Taszner
    • Justyna Rybka
    • Karolina Chromik
    • Agnieszka Kołkowska-Leśniak
    • Edyta Subocz
    • Łukasz Targoński
    • Paulina Ceklarz
    • Magdalena Witkowska
    • Katarzyna Domańska-Czyż
    • Agnieszka Giza
    • Małgorzata Kobylecka
    • Conrad-Amadeus Voltin
    • Joanna Romejko-Jarosińska
    • Beata Ostrowska
    • Monika Świerkowska
    • Agnieszka Druzd-Sitek
    • Michał Kurlapski
    • Marta Bednarek
    • Grzegorz Romanowicz
    • Ryszard Swoboda
    • Joanna Góra-Tybor
    • Janusz Hałka
    • Tomasz Wróbel
    • Sebastian Giebel
    • Grzegorz Helbig
    • Ewa Lech-Marańda
  • Show Details

    P108 (P108) Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II AERN Trial

    • Paul J. Bröckelmann
    • Ina Bühnen
    • Josée M. Zijlstra
    • Stephan Mathas
    • Katrin S. Roth
    • Maria Garcia-Marquez
    • Christian Sillaber
    • Julia Meissner
    • Alexander Fosså
    • Richard Greil
    • Karolin Trautmann-Grill
    • Johannes Rosenbrock
    • Wouter J. Plattel
    • Hans A. Schlösser
    • Carsten Kobe
    • Michael Fuchs
    • Peter Borchmann
    • Christian Baues
  • Show Details

    P109 (P109) Are refractory/relapsed Hodgkin lymphoma patients can be recognized earlier?

    • Boglárka Dobó
    • Dávid Tóthfalusi
    • László Imre Pinczés
    • Zsófia Miltényi
    • Árpád Illés
  • Show Details

    P110 (P110) Autologous stem cell transplantation in relapsed/refractory classic Hodgkin lymphoma after PD-1 inhibitors salvage regimens is effective in third- or fourth-line therapy

    • Polina Kotselyabina
    • Evgenia Borzenkova
    • Andrey Chekalov
    • Kirill Lepik
    • Liudmila Fedorova
    • Artem Ivanov
    • Elena Lepik
    • Elena Kondakova
    • Ivan Moiseev
    • Natalia Mikhailova
    • Alexander Kulagin
  • Show Details

    P111 (P111) C-MOPP chemotherapy is a highly efficacious regimen for patients with relapsed classical Hodgkin lymphoma following PD-1 inhibitor treatment failure.

    • Stephen Ma
    • Shahla Vilcassim
    • Pasquale Fedele
    • George Grigoriadis
    • Michael Low
    • Gareth P. Gregory
    • Stephen Opat
    • Michael Gilbertson
  • Show Details

    P112 (P112) Coformulated Favezelimab and Pembrolizumab (pembro) Versus Chemotherapy (chemo) in Patients (Pts) With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) Refractory to Anti–PD-1 Therapy: The Phase 3 KEYFORM-008 Study

    • David Lavie
    • John Timmerman
    • Ramón García-Sanz
    • Won-Seog Kim
    • Tae Min Kim
    • Abraham Avigdor
    • Daan Dierickx
    • Deepa Jagadeesh
    • Daniel Molin
    • Muhit Ozcan
    • Omur Gokmen Sevindik
    • Hayder Saeed
    • Yulia Sidi
    • Pallavi Pillai
    • Rushdia Yusuf
    • Alex F. Herrera
  • Show Details

    P113 (P113) Dose-dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-year Long Term Follow Up

    • Ryan Lynch
    • Ryan Cassaday
    • Stephen Smith
    • Andrew Cowan
    • Edus H. Warren
    • Mazyar Shadman
    • Brian Till
    • Chaitra Ujjani
    • Karolyn Morris
    • Heather Rasmussen
    • Jenna Voutsinas
    • Ajay K. Gopal
  • Show Details

    P114 (P114) Early Progression of Disease Predicts Poor Survival in Patients with Classic Hodgkin Lymphoma: Czech Hodgkin Lymphoma Study Group analysis

    • Vít Procházka
    • Alice Sýkorová
    • Alexandra Kredátusová
    • Marie Lukášová
    • Pavla Štěpánková
    • Tomáš Papajík
  • Show Details

    P115 (P115) Efficacy and safety of prolgolimab monotherapy or in combination with bendamustine in second-line therapy for r/r classic Hodgkin lymphoma: trial in progress (Prolgo-HL)

    • Liudmila Fedorova
    • Kirill Lepik
    • Polina Kotselyabina
    • Anastasia Semenova
    • Valerie Shpirko
    • Stanislav Volchenkov
    • Vladislav Markelov
    • Andrey Chekalov
    • Ilya Zyuzgin
    • Gayane Tumyan
    • Natalia Mikhailova
    • Alexander Kulagin
  • Show Details

    P116 (P116) Extended Follow-up from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412)

    • Catherine Diefenbach
    • Opeyemi Jegede
    • Stephen M. Ansell
    • Christian Steidl
    • Yasodha Natkunam
    • David W. Scott
    • Neha Mehta-Shah
    • Jennnifer E. Amengual
    • Christopher J. Forlenza
    • Peter Cole
    • Nancy L. Bartlett
    • Kevin David
    • Ranjana H. Advani
    • Richard F. Ambinder
    • Sachdev P. Thomas
    • Sami Ibrahimi
    • Brad S. Kahl
  • Show Details

    P117 (P117) Frequency and indicators of primary refractoriness in low-risk non-bulky early-stage Hodgkin’s lymphoma patients and negative interim PET – report from the RAFTING trial

    • Kateryna Filonenko
    • Eva Domingo-Domènech
    • Javier Nunez
    • Cecilia Carpio
    • Alessandra Romano
    • Corrado Tarella
    • Antonia Rodríguez Izquierdo
    • Ramon Garcia
    • Livio Trentin
    • Manuel Gotti
    • Michał Kurlapski
    • Marta Bednarek
    • Andrea Gallamini
    • Jan Maciej Zaucha
  • Show Details

    P118 (P118) Gemcitabine and Vinorelbine as 3rd line Chemotherapy for Primary Refractory/relapsing Hodgkin Lymphoma-Outcome and Toxicity Profile

    • Asmaa Hamoda
    • reham khedr
    • hany abdelrahman
    • naglaa elkinaii
    • iman zaki
    • engy mohamed
  • Show Details

    P119 (P119) Inclusion of Brentuximab vedotin in salvage regimens before transplant benefits relapsed/refractory Hodgkin lymphoma patients in a real-world setting - a multicenter study in Portugal

    • Pedro Santos
    • Sara Tavares
    • Catarina Costa
    • Miguel Neto
    • Isabel Paulos Mesquita
    • Catarina Silva
    • Filipe R. Pinto
    • Ana Tomé
    • Rita Gerivaz
    • Alexandra Monteiro
    • Rita Coutinho
    • Adriana Roque
    • Ana Luísa Pinto
    • Margarida Badior
    • Teresa Ribeiro
    • Marco Dias
    • Ana Vagos Mata
    • Tatiana Mendes
    • Francisca Miranda
    • Filipa Mousinho
    • Renata Cabral
    • Sofia Ramalheira
    • Mafalda Alpoim
    • Bruno Mesquita
    • Francesca Pierdomenico
    • Maria Gomes da Silva
  • Show Details

    P120 (P120) KEYNOTE-B68: Updated efficacy and safety of pembrolizumab every six weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL)

    • Andrew McDonald
    • Estelle Verburgh
    • Manuel Gotti
    • Antonio Pinto
    • Jan Maciej Zaucha
    • Vladimir Ivanov
    • Vladimir Melnichenko
    • Heidi Mocikova
    • Muhit Ozcan
    • Caterina Patti
    • João Farias
    • Iara Goncalves
    • Olha Kuchkova
    • Jiri Mayer
    • Güray Saydam
    • Sarah Tomassetti
    • Kumudu Pathiraja
    • Katherine Ryland
    • Rushdia Yusuf
    • Wojciech Jurczak
  • Show Details

    P121 (P121) Nivolumab based salvage in Relapsed/Refractory Hodgkin Lymphoma: experience from a tertiary care hospital in north India

    • Sanjeev Sanjeev
    • Deep Gala
    • Sauvik Saha
    • Manish Kumar Singh
    • Aftab Nazar
    • Manish ora
    • Dinesh chandra
    • Khaliqur Rahman
    • Ruchi Gupta
    • Rajesh Kashyap
  • Show Details

    P122 (P122) Open-label phase 1 study to evaluate the safety of SGN-35T in patients with relapsed/refractory CD30-expressing lymphoid malignancies (SGN35T-001; trial in progress)

    • Tatyana Feldman
    • Radhakrishnan Ramchandren
    • Hun Ju Lee
    • Gizelle Popradi
    • Graham P. Collins
    • Daniel Morillo
    • Mingjin Yan
    • Tara L. Chen
    • Youn H. Kim
  • Show Details

    P123 (P123) Outcome of treatment with the anti-PD-1 monoclonal antibodies nivolumab and pembrolizumab in patients with classical Hodgkin lymphoma — A retrospective analysis on consecutive patients from a well-defined region.

    • Zaid Mansur
    • Elin Lundin
    • Lotta Hansson
    • Björn Engelbrekt Wahlin
    • Marzia Palma
  • Show Details

    P124 (P124) Outcomes in patients with relapsed/refractory Hodgkin lymphoma after failure following frontline brentuximab vedotin-based treatment

    • Shin Yeu Ong
    • Lu Chen
    • Reid Merryman
    • Harsh Shah
    • Robert Stuver
    • Ann S. LaCasce
    • Ayo Falade
    • Kelsey Baron
    • Nivetha Ganesan
    • Tiffany Chang
    • Urshila Durani
    • Tamer Othman
    • Philippe Armand
    • Matthew Mei
    • Alison J. Moskowitz
    • Alex F. Herrera
  • Show Details

    P125 (P125) Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study

    • Alexandra Dreyfuss
    • Nivetha Ganesan
    • Alvaro Alencar
    • Alexander Boardman
    • Philip Caron
    • Tiffany Chang
    • Theresa Davey
    • Kevin David
    • Ahmet Dogan
    • Zachary Epstein-Peterson
    • Lorenzo Falchi
    • Beatrice Fregonese
    • Paola Ghione
    • Paul Hamlin
    • Steven Horwitz
    • Brandon Imber
    • Andrew Intlekofer
    • Derek Isrow
    • Erel Joffe
    • William Johnson
    • Anita Kumar
    • Michael Lariviere
    • Jennifer Lue
    • Efrat Luttwak
    • Michael McNicholas
    • Zachary Moore
    • Brittney Munayirji
    • Ariela Noy
    • Colette Owens
    • Lia Palomba
    • Jaldhi Patel
    • John Plastaras
    • Alayna M. Santarosa
    • Heiko Schöder
    • Gunjan Shah
    • Raphael E. Steiner
    • Robert Stuver
    • Jakub Svoboda
    • Pallawi Torka
    • Santosha Vardhana
    • Andrew Zelenetz
    • Gilles Salles
    • Joachim Yahalom
    • Craig H. Moskowitz
    • Alison Moskowitz
  • Show Details

    P126 (P126) Pembrolizumab in Combination with Salvage Chemotherapy for First-Relapsed or Refractory Classical Hodgkin Lymphoma: The Multicenter Phase II Pembro-CORE Study (Trial in Progress)

    • Hishan Tharmaseelan
    • Sarah Gillessen
    • Ina Bühnen
    • Helen Kaul
    • Carsten Kobe
    • Wolfram Klapper
    • Michael Fuchs
    • Sven Borchmann
    • Paul J. Bröckelmann
    • Peter Borchmann
    • Bastian von Tresckow
  • Show Details

    P127 (P127) Phase II Trial Evaluating the Anti-CD47 Antibody Magrolimab in Combination with Pembrolizumab in Patients with Relapsed / Refractory Classic Hodgkin Lymphoma

    • Joseph Schroers-Martin
    • Michael Spinner
    • Reid Merryman
    • Cheryl Chang
    • Austin Yeung
    • Chandley Silin
    • May Powell
    • Philippe Armand
    • Margaret A. Shipp
    • Ranjana H. Advani
  • Show Details

    P128 (P128) Preliminary Results of the Phase 2 Study Evaluating the Safety and Efficacy of Pembrolizumab (KEytruda) with Bendamustine (TREanda) in Relapsed/Refractory Hodgkin Lymphoma (KEsTREL-01, NCT04510636)

    • Chathuri Abeyakoon
    • Semira Sheikh
    • Lisa Wang
    • Tomohiro Aoki
    • Sita Bhella
    • Robert Kridel
    • Vishal Kukreti
    • Anca Prica
    • Abi Vijenthira
    • Rob Laister
    • Michael Crump
    • John Kuruvilla
  • Show Details

    P129 (P129) Radiomic and biological biomarkers in relapsed/ refractory classical Hodgkin Lymphoma: an analysis from the ANIMATE study

    • Aisling Barrett
    • Amy A. Kirkwood
    • Maria Micaela Vidal
    • Victoria Warbey
    • Cathy Burton
    • Sharon Barrans
    • Tracey Mell
    • Reuben Tooze
    • John R Davies
    • David Westhead
    • Charlotte Tyson
    • Emma Lawrie
    • Laura Clifton-Hadley
    • Fiona Miall
    • Rifca LeDieu
    • Elizabeth H. Phillips
    • Wendy Osborne
    • Dominic Culligan
    • Nimish Shah
    • Bryson Pottinger
    • David Cunningham
    • Ruth Pettengell
    • Nicolas Martinez-Calle
    • Peter Johnson
    • Eve Gallop-Evans
    • Karl Peggs
    • Stephen Booth
    • Arzhang Ardavan
    • Sally F. Barrington
    • Graham P. Collins
  • Show Details

    P130 (P130) Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

    • Robert Stuver
    • Santosha Vardhana
    • Nivetha Ganesan
    • Neena Mahajan
    • Alexander Boardman
    • Philip Caron
    • Kevin David
    • Zachary Epstein-Peterson
    • Lorenzo Falchi
    • Paola Ghione
    • Paul Hamlin
    • Francisco Hernandez-Ilizaliturri
    • Steven Horwitz
    • Andrew Intlekofer
    • William Johnson
    • Reem Karmali
    • Anita Kumar
    • Jennifer Lue
    • Efrat Luttwak
    • Ariela Noy
    • Colette Owens
    • Maria Palomba
    • Gilles Salles
    • Heiko Schoder
    • David Sermer
    • Raphael E. Steiner
    • Pallawi Torka
    • Andrew Zelenetz
    • Gottfried von Keudell
    • Alison Moskowitz
  • Show Details

    P131 (P131) Results of allogeneic stem cell transplantation in Hodgkin lymphoma – long term experience.

    • Zuzana Rusináková
    • Andrej Vranovský
    • Miriam Ladická
    • Silvia Cingeľová
    • Ladislav Sopko
    • Eva Bojtárová
    • Eva Mikušková
    • Ľuboš Drgoňa
  • Show Details

    P132 (P132) Richter transformation of CLL to Hodgkin lymphoma

    • Mária Maco
    • Heidi Mocikova
    • Markéta Kalinová
    • Zuzana Prouzová
    • Patrik Flodr
    • Anna Panovská
    • Tomáš Arpáš
    • Martin Šimkovič
    • Tomáš Kozák
  • Show Details

    P133 (P133) Award winning Serum TARC monitoring during routine follow-up leads to early diagnosis of relapse in classic Hodgkin lymphoma

    • Sophie Teesink
    • Lydia Visser
    • Kylie Keijzer
    • Bart-Jan Kroesen
    • Marcel Nijland
    • Anke van den Berg
    • Arjan Diepstra
    • Wouter J. Plattel
  • Show Details

    P134 (P134) THE BELIEVE STUDY: EFFECTIVENESS AND SAFETY FOR RE-TREATMENT WITH BRENTUXIMAB-VEDOTIN IN RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA: A RETROSPECTIVE MEDICAL CHART REVIEW IN SPAIN. NCT:04998331

    • Anna Sureda-Balari
    • Ramón García-Sanz
    • Eva Domingo-Domènech
    • Francisco J. Capote
    • Antonio Gutierrez
    • Antonia Rodríguez Izquierdo
    • Marta Grande
    • Lourdes Baeza-Montañez
  • Show Details

    P135 (P135) The coincidence of relapsed Hodgkin lymphoma and ovarian carcinoma as a role-model for ctDNA MRD monitoring

    • Veronika Hanáčková
    • Jan Grohmann
    • Patrik Flodr
    • Tomáš Papajík
    • Jana Navrátilová
    • Vít Procházka
  • Show Details

    P136 (P136) The prognostic value of ΔSUVmax and TARC in the first-line treatment of classical Hodgkin lymphoma

    • László Imre Pinczés
    • Dávid Tóthfalusi
    • Boglárka Dobó
    • Sándor Barna
    • Bence Farkas
    • Ildikó Garai
    • Zsolt Fejes
    • Béla Nagy Jr.
    • Árpád Illés
    • Zsófia Miltényi
  • Show Details

    P137 (P137) Updated Analysis of a Phase 1/2 Study Evaluating Pembrolizumab (pembro) Plus the Anti–Lymphocyte-Activation Gene 3 (LAG-3) Antibody Favezelimab for Anti–PD-1–Naive Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

    • Nathalie A. Johnson
    • David Lavie
    • Peter Borchmann
    • Gareth P. Gregory
    • Alex F. Herrera
    • Leonard Minuk
    • Vladan Vucinic
    • Philippe Armand
    • Abraham Avigdor
    • Robin Gasiorowski
    • Yair Herishanu
    • Colm Keane
    • John Kuruvilla
    • Rachel Marceau West
    • Pallavi Pillai
    • Rushdia Yusuf
    • John Timmerman
  • Show Details

    P138 (P138) Updated Analysis of a Phase 1/2 Study Evaluating Pembrolizumab (pembro) Plus the Anti–Lymphocyte-Activation Gene 3 (LAG-3) Antibody Favezelimab for Heavily Pretreated Anti–PD-1–Refractory Classical Hodgkin Lymphoma (cHL)

    • John Timmerman
    • David Lavie
    • Nathalie A. Johnson
    • Abraham Avigdor
    • Peter Borchmann
    • Charalambos Andreadis
    • Ali Bazargan
    • Gareth P. Gregory
    • Colm Keane
    • Inna Tzoran
    • Vladan Vucinic
    • Pier Luigi Zinzani
    • Rachel Marceau West
    • Pallavi Pillai
    • Rushdia Yusuf
    • Alex F. Herrera

General Information

Conference Office

Gürzenich Cologne Martinstraße 29-37 50677 Cologne During the Conference the Secretariat can be contacted at Phone: +49 (0) 173 939 07 30 Email: info@tca-hanke.de

Opening Hours of the Conference Secretariat

Saturday, October 26, 2024 07:00–18:00 Sunday, October 27, 2024 07:00–19:30 Monday, October 28, 2024 07:00–16:00

Accomodation

For accomodation support, please contact the conference management: Phone: +49 (0) 2102 . 669 36 Email: info@tca-hanke.de

Name Badge

Please make sure to always wear your badge at the conference. If you lose your badge, we will have to charge you a replacement fee.

Catering

During the breaks, complimentary coffee, fruit and refreshments will be available.

Cloakroom

The cloakroom is located in the basement.

Conference Language

The conference language is English.

Continuing Medical Education

The 13th International Symposium on Hodgkin Lymphoma is certified by the European Board for Accreditation in Hematology (formerly EHA) with 17.5 EBAH credit points. Please collect your certificates before departure at the registration desk (in the entrance hall of the Gürzenich).

Insurance

The meeting organizers cannot accept liability for personal injuries sustained to Conference participants or for loss or damage of their personal belongings, neither during nor as a result of the meeting.

Internet

There will be free wifi at the Gürzenich Conference Center. Further details and access codes will be provided on site. You can also use the two on-site internet terminals for web browsing and web-based email access.

Prayer Room

A nondenominational prayer room will be available in the conference center. For further details, please contact the Conference Secretariat.

Registration

Pre-registration will close on October 25, 2024. All registrations re- ceived on or after October 26 will be considered as on-site registra- tions and will be charged the on-site fee. Full registration will include access to the scientific sessions and exhibition, a copy of the program, the welcome reception on Saturday (October 26) and all refreshment breaks. You will also receive a name tag; please wear this name tag at all conference events including the scientific symposia. No refunds will be given.

Speakers Ready Room

The Speakers Ready Room is located next to the registration desk on the ground floor of the Gürzenich Conference Center. Speakers are requested to hand in their PowerPoint presentations in 16:9 format saved on a stick at least 3 hours before their session or the day before if the session starts early in the morning. We can only accept Microsoft PowerPoint files for upload to the conference system. It is not permit- ted to use your own laptops or other devices for uploading the files.

Non-Smoking

Please note that there will be a strict non-smoking policy at all conference facilities.

Transportation

The airports closest to Cologne City are Cologne Bonn Airport (CGN; 15 km) and Düsseldorf Airport (DUS; 45 km). From Cologne Bonn Airport you can reach Cologne central station by regional rail in about 30 minutes; from Frankfurt Airport to Cologne it takes only an hour by InterCity Express (ICE) and from Düsseldorf Airport about 45 minutes. Cologne central station is within walking distance (about 10 minutes) from the Gürzenich Conference Center and the Dorint Hotel. You can also take bus no. 132 and get off at “Gürzenichstraße”. The other hotels recommended by the Conference Organization can easily be reached by public transport. Cologne has an efficient public trans- port system, but the recommended hotels, the venue as well as other places of interest are within a comfortable walking distance from each other. For those who are traveling by car, we recommend to use the parking ground “Heumarkt” (about 3 minutes walking distance from the Gürzenich). If you want to take a taxi, you can either get in directly at one of the numerous taxi stands or you can order a taxi by phone from one of the taxi call centers (+49 221 170000 or +49 221 2882). Uber and Lyft or other ride sharing services do not operate reliably in Cologne or are not available at all. A taxi will most of the time be the better option.

Welcome Reception

On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join the poster session which is accompanied by a Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin Lymphoma research and treatment. Drinks and snacks will be provided.

Acknowledgements

Academic Sponsors

Legal Info

International Symposium on Hodgkin Lymphoma

Prof. Peter Borchmann, MD. German Hodgkin Study Group (GHSG) Gleueler Str. 269-273 50935 Köln Phone: +49 (0)221-478 5933 Fax: +49 (0)221-478 3778

Responsible for Content Provided

In accordance with the German Act for Telemedia Services (TMG), § 55 Abs. 2 RStV (section 55, subsection 2 broadcast services state treaty): Prof. Peter Borchmann, MD.

Obligatory Information

Legal Entitiy: The University Hospital of Cologne is a Public Law Institution. Legal Representation: The University Hospital of Cologne is represented by the Board of Directors, in turn represented by: Prof. Dr. Edgar Schömig, CEO and medical director Günter Zwilling, Director of finance Kerpener Str. 62 D-50937 Köln

Scientific Organisation

Peter Borchmann, MD, Symposium and GHSG Chairman Sven Borchmann, MD, PhD, Symposium Co-Chair Paul J. Bröckelmann, MD, Symposium Co-Chair Dennis A. Eichenauer, MD, Symposium Co-Chair German Hodgkin Study Group Department I for Internal Medicine University Hospital of Cologne Kerpener Straße 62, D-50924 Cologne Phone: +49 (0) 221 . 478-5933 Fax: +49 (0) 221 . 478-3778 Email: info@hodgkinsymposium.org Further Information: www.hodgkinsymposium.org

Conducting Organisation

KARO – KML Academic Research Organisation GmbH Gleueler Str. 176-178, D–50935 Köln Phone +49 221 560 779-43 Fax: +49 221 560 779-44 CEO: Dr. Birgit Fath, Michael Fuchs

Conference Management & Industrial Exhibition Secretariat

Gabriele Hanke Travel & Congress Activities Marienburger Str. 8; D-40883 Ratingen Phone: +49 (0) 2102 . 669 36 Fax: +49 (0) 2102 . 9648 29 Email: info@tca-hanke.de

Not Found

Back to start